SG Americas Securities
SRPT icon

SG Americas Securities’s Sarepta Therapeutics SRPT Stock Holding History

SG Americas Securities’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-22,000
Closed -$308K – 3466
2020
Q3 		$308K Buy
+22,000
New +$3.34M ﹤0.01% 1925

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SG Americas Securities's SRPT Position: Q1 2026 in Review

SG Americas Securities increased its Sarepta Therapeutics (SRPT) stake by 192% in Q1 2026, buying an estimated $7.12M and bringing the position to 559,063 shares worth $12.2M. The position accounts for 0.01% of the portfolio, ranked #719.

SG Americas Securities first reported a position in SRPT in Q3 2013 and has held it in 34 quarters since. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • SG Americas Securities held 559,063 shares of Sarepta Therapeutics worth $12.2M as of Q1 2026.
  • SG Americas Securities bought 367,692 Sarepta Therapeutics shares in Q1 2026, an estimated $7.12M.
  • Sarepta Therapeutics made up 0.01% of SG Americas Securities's portfolio in Q1 2026, its #719 holding.
  • SG Americas Securities first reported a position in Sarepta Therapeutics in Q3 2013 and has held it in 34 quarters since.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.